Prenatal screening for cystic fibrosis carriers: An economic evaluation

American Journal of Human Genetics

Volumn 63, Issue 4, 1998, Pages 1160-1174

  Rowley, Peter T ^a   Loader, Starlene ^a   Kaplan, Robert M ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMAN; PRENATAL SCREENING; PRIORITY JOURNAL;

EID: 0032231384     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/302042     Document Type: Article

References (56)

1. Asch DA, Hershey JC, Pauly MV, Patton JP, Jedrziewski MK, Mennuti MT (1996) Genetic screening for reproductive planning: methodological and conceptual issues in policy analysis. Am J Public Health 86:684-690
2. Asch DA, Patton JP, Hershey JC, Mennuti MT (1993) Reporting the results of cystic fibrosis carrier screening. Am J Obstet Gynecol 168:1-6
3. Attanasio E, Gallanello R, Rossi-Mori A (1980) La preventione delle malattie microcitemice. Editioni Minerva Medica, Roma
4. Barden HS, Kessel R, Schuett VE (1984) The costs and benefits of screening for PKU in Wisconsin. Soc Biol 31:1-17
5. Botkin JR (1990) Prenatal screening: professional standards and limits of prenatal choice. Obstet Gynecol 75:875-880
6. Brock DJH (1996) Prenatal screening for cystic fibrosis: 5 years' experience reviewed. Lancet 347:148-150
7. Bush JW, Chen MM, Patrick DL (1973) Cost-effectiveness using a health status index: analysis of the New York State PKU screening program. In: Berg R (ed) Health status index. Hospital Research and Educational Trust, Chicago, pp 172-208
8. Bush JW, Fanshel S, Chen MM (1972) Analysis of a tuberculin testing prograin using a health status index. Soc Econ Plann Sci 6:49-69
9. Chamberlain J (1978) Human benefits and costs of a national screening programme for neural-tube defects. Lancet 2: 1293-1296
10. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, et al (1996) Accessing genetic information with high-density DNA arrays. Science 274:610-614
11. Cuckle HS, Richardson GA, Sheldon TA, Quirke TA (1995) Cost effectiveness of antenatal screening for cystic fibrosis. BMJ 311:1460-1464
12. Cutting GR (1997) Genetic epidemiology and genotype/phenotype correlations. Paper presented at the National Institutes of Health Consensus Development Conference "Genetic Testing for Cystic Fibrosis," Bethesda, April 14-16
13. Donaldson C, Shackley P, Abdalla M (1997) Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ 6:145-159
14. Drummond MF, Davies LM (1991) Economic analysis alongside clinical trials: revisiting the methodological issues. Int Technol Assess Health Care 7:561-573
15. Eddy DM (1989) Screening for breast cancer. Ann Intern Med 111:389-399
16. Epstein KA, Schneiderman LJ, Bush JW, Zettner A (1981) The "abnormal" screening serum thyroxine (T4): analysis of physician response, outcome, cost and health effectiveness. J Chronic Dis 34:175-190
17. Evers-Kiebooms G, Denayer L, Van den Berghe H (1990) A child with cystic fibrosis. II. Subsequent family planning decisions, reproduction and use of prenatal diagnosis. Clin Genet 37:207-215
18. Ganiats TG (1996) Prenatal screening and genetic amniocentesis programs by cost-effectiveness analysis: a re-evaluation. Med Decis Making 16:45-50
19. Garber AM, Fenerty JP (1991) Costs and benefits of prenatal screening for cystic fibrosis. Med Care 29:473-489
20. Gill M, Murday V, Slack J (1987) An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration. Soc Sci Med 24:725-731
21. Ginsberg G, Blau H, Kerem E, Springer C, Kerem B-S, Akstein E, Greenberg A, et al (1994) Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population. Health Econ 3:5-23
22. Hagard S, Carter FA (1976) Preventing the birth of infants with Down's syndrome: a cost-benefit analysis. Br Med J 1: 753-756
23. Henderson JB (1982) Measuring the benefits of screening for open neural tube defects. J Epidemiol Commun Health 36: 214-219
24. Hilgers T, Horan DJ (1972) Abortion and social justice. Sheet & Ward, New York
25. Hollenberg J (1988) SMLTREE, version 2.9. Computer program available from J Hollenberg, Roslyn, NY
26. Klinger KW (1997) Genetic testing technologies. Paper presented at the National Institutes of Health Consensus Development Conference "Genetic Testing for Cystic Fibrosis," Bethesda, April 14-16
27. Levenkron JC, Loader S, Rowley PT (1997) Carrier-screening for cystic fibrosis: test acceptance and one year follow-up. Am J Med Genet 73:378-386
28. Lieu TA, Watson SE, Washington AE (1994) The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 84:903-912
29. Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr, Rowley PT (1996) Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 59:234-247
30. Miedzybrodzka Z, Semper J, Shackley P, Abdalla M, Donaldson C (1995) Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay. J Med Genet 32:282-283
31. Mennie ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, Whyte DA, et al (1992) Prenatal screening for cystic fibrosis. Lancet 340:214-216
32. Modell B, Kuliev AM (1991) Services for thalassemia as a model for cost-benefit analysis of genetic services. J Inherit Metab Dis 14:640-651
33. _ (1993) A scientific basis for cost-benefit analysis of genetics services. Trends Genet 9:46-52
34. Morris DT (1994) Cost containment and reproductive autonomy: prenatal genetic screening and the American Health Security Act of 1993. Am J Law Med 20:295-316
35. National Institute of Coronary Heart Disease National Registry for Amniocentesis Study Group (1976) Midtrimester amniocentesis for prenatal diagnosis. JAMA 236: 1471-1476
36. National Institutes of Health (1997) Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference statement, "Genetic Testing for Cystic Fibrosis," Bethesda, April 14-16
37. Nelson WB, Swint JM, Caskey CT (1978) A comment on the benefits and costs of genetic screening. Am J Hum Genet 30:663-665
38. Old JM, Fitches A, Heath C, Thein SL, Weatherall DJ (1986) First-trimester fetal diagnosis for haemoglobinopathies: report on 200 cases. Lancet 2:763-766
39. Ostrowsky JT, Lippman A, Scriver CR (1985) Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health 75:732-736
40. Riordan JR, Rommens J, Kerem B, Alon N, Rozmahel R, Grzekzak Z, Zielenski J, et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073
41. Rommens JH, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, et al (1989) Identification of the cystic fibrosis gene: chromosomal walking and jumping. Science 245:1059-1065
42. Rowley PT, Loader S, Levenkron JC (1997) Cystic fibrosis carrier population screening: a review. Genet Testing 1: 53-59
43. Rowley PT, Loader S, Levenkron JC, Phelps CE (1993) Cystic fibrosis carrier screening: knowledge and attitudes of prenatal care providers. Am J Prev Med 9:261-266
44. Sadovnick AD, Baird PA (1981) A cost-benefit analysis of prenatal detection of Down syndrome and neural tube defects in older mothers. Am J Med Genet 10:367-378
45. Schulman KA, Linas BP (1997) Pharmacoeconomics: state of the art in 1997. Annu Rev Public Health 18:529-548
46. Schwartz M, Brandt NJ, Skovby F (1993) Screening for carriers of cystic fibrosis among pregnant women: a pilot study. Eur J Hum Genet 1:239-244
47. Torrance GW, Zipursky A (1984) Cost effectiveness of antepartum prevention of Rh immunization. Clin Perinatol 11: 267-281
48. US Congress Office of Technology Assessment (1979) A review of selected federal vaccine and immunization policies: based on case studies of pneumococcal vaccine. US Government Printing Office, Washington, DC
49. _ (1992) Cystic fibrosis and DNA tests: implications of carrier screening. US Government Printing Office, Washington, DC
50. Watson EK, Mayall E, Chapple J, Dalziel M, Harrington K, Williams C, Williamson R (1991) Screening for carriers of cystic fibrosis through primary health care services. BMJ 303:504-507
51. Weinstein MC (1980) Estrogen use in postmenopausal women - costs, risks, and benefits. N Engl J Med 303: 308-316
52. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253-1258
53. Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716-721
54. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL (1995) Cystic fibrosis. In Scriver CR , Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 7th ed. McGraw-Hill, New York, pp 3799-3876
55. Wertz DC, Janes SR, Rosenfield JM, Erbe RW (1992) Attitudes toward the prenatal diagnosis of cystic fibrosis: factors in decision making among affected families. Am J Hum Genet 50:1077-1085
56. Wilfond BS, Fost N (1992) The introduction of cystic fibrosis carrier screening into clinical practice: policy considerations. Milbank Q 70:629-659